Polycystic ovarian syndrome treatment market

Polycystic Ovary Syndrome (PCOS) Treatment Market, By Drug Class (Oral contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs and Diuretics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Request Free Sample

Apr 2023
CMI1589
177 Pages
Excel & Pdf
Pharmaceutical

Summary

The global polycystic ovary syndrome (PCOS) treatment market is estimated to be valued at US$ 1,086.6 million in 2023 and is expected to exhibit a CAGR of 4.86% during the forecast period (2023-2030).

Analysts’ Views on Global Polycystic Ovary Syndrome (PCOS) Treatment Market:

The global polycystic ovary syndrome (PCOS) treatment market growth can be driven over the forecast period due to an increase in research and development activities by the key market players. For instance, in April 2019, a study published in The Journal of Clinical Endocrinology & Metabolism reported identifying DENND1A, a gene involved in male hormone production, which plays a major role in the development of polycystic ovary syndrome.

Figure 1. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Share (%), by Drug Class, 2023

Global Polycystic Ovary Syndrome (PCOS) Treatment Market – Driver

Increasing research and development activities

Research and development in polycystic ovary syndrome is also expected to aid in growth of the market. For instance, in June 2020, ‘Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis’ – a study funded by the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and National Institute of Diabetes and Digestive and Kidney Diseases, reported that polycystic ovary syndrome may have at least two different subtypes.

Figure 2. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Value (US$ Million), by Region, 2023

Global Polycystic Ovary Syndrome (PCOS) Treatment Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global polycystic ovary syndrome (PCOS) treatment market over the forecast period due to the increasing prevalence of polycystic ovary syndrome. For instance, in December 2022, The Centers for Disease Control and Prevention, the national public health agency of the U.S., published a data, according to which polycystic ovary syndrome (PCOS) is one of the common causes of female infertility, which affect 6% to 12% (as many as 5 million) of the U.S. women of reproductive age.

Global Polycystic Ovary Syndrome (PCOS) Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global polycystic ovary syndrome (PCOS) treatment market. For instance, in July 2020, a article was published in BioMed Central, a scientific open access publisher, stated data suggest that women with polycystic ovary syndrome (PCOS) may be at potentially higher risk for severe COVID-19 also due to low vitamin D levels, which may be further aggravated by reduced sun exposure due to COVID-19-related quarantine measures.

Polycystic Ovary Syndrome (PCOS) Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2022	Market Size in 2023:	US$ 1,086.6 Mn
Historical Data for:	2017 to 2021	Forecast Period:	2023 to 2030
Forecast Period 2023 to 2030 CAGR:	4.86%	2030 Value Projection:	US$ 1,514.6 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Class: Oral Contraceptives, Insulin Sensitizing Agents, Anti- Depressants, Ornithine Decarboxylase Inhibitors, Aromatase inhibitors & SERMs, Diuretics By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., Evotec SE, McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical and Sun Pharmaceutical Industries Ltd., Bayer AG
Growth Drivers:	High prevalence of polycystic ovary syndrome Research and development
Restraints & Challenges:	Unavailability of U.S. Food and Drug Administration (FDA) approved drugs Alternative treatment options

Global Polycystic Ovary Syndrome (PCOS) Treatment Market Segmentation:

The global polycystic ovary syndrome (PCOS) treatment market report is segmented into drug class, distribution channel and region.

Based on Drug Class, the polycystic ovary syndrome (PCOS) treatment segmented into oral contraceptives, insulin sensitizing agents, anti-depressants, ornithine decarboxylase inhibitors, aromatase inhibitors & SERMS, diuretics, out of which the aromatase inhibitors and & SERMs, is expected to dominate the global polycystic syndrome (PCOS) treatment market over the forecast period, which is attributed to the increase in the effectiveness of the drug.

Based on Distribution Channel, the polycystic ovary syndrome (PCOS) treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies, out of which the hospital pharmacies segment is expected to dominate over the forecast period due to an increase in the drug demand for polycystic ovary syndrome such as oral contraceptives etc.

Based on Region, the polycystic ovary syndrome (PCOS) treatment market is segmented into regions, which include North America, Latin America, Europe, Asia Pacific, Middle East, and Africa, out of which the North America is expected to dominate the market over the forecast period and this is attributed to increase in the launch of the drugs by the key market players.

Global Polycystic Ovary Syndrome (PCOS) Treatment Market Cross Sectional Analysis:

In drug class segment, oral contraceptives hold a dominant segment in North America region due to the increasing no of drugline treatment for polycystic ovary syndrome. For instance, in October 2020, an article was published in American College of Obstetricians and Gynecologists, a professional association of physicians specializing in obstetrics and gynecology, according to which birth control pills can be used for long-term treatment in women who do not wish to get pregnant, which means the pills contain both estrogen and progestin.

Global Polycystic Ovary Syndrome (PCOS) Treatment Market: Key Developments

Increasing adoption of inorganic growth strategies, such as acquisition and collaboration by key players in the market for the development of novel drug, is expected to n drive the market growth over the forecast period. For instance, in January 2020, Evotec, a biotechnology company, and Bayer AG, a pharmaceutical and biotechnology company, had announced collaboration expansion to develop drug candidates for polycystic ovary syndrome (PCOS).

Global Polycystic Ovary Syndrome (PCOS) Treatment Market: Restraint

Alternative treatment option present in the market

The global polycystic ovary syndrome (PCOS) treatment market can be hindered by the alternative treatment options for polycystic ovary syndrome treatment. For instance, in February 2021, an article was publiushed by the National Center for Biotechnology Information, according to which, using complementary and alternative medicine (CAM) including acupuncture, Chinese herbal medicine, Tai Chi, yoga, and Qigong can also effectively treat PCOS with fewer adverse reactions.

Global Polycystic Ovary Syndrome (PCOS) Treatment Market - Key Players

Key companies covered as a part of this study Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Evotec SE, Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical and Sun Pharmaceutical Industries Ltd., Bayer AG, and other prominent players

Definition: A hormonal disorder causing enlarged ovaries with small cysts on the outer edges. The cause of polycystic ovary syndrome is not well understood, but may involve a combination of genetic and environmental factors symptoms include menstrual irregularity, excess hair growth, acne and obesity.

Table of Content

Table of Contents

*Browse 24 market data tables and 28 figures on “Polycystic Ovary Syndrome (PCOS) Treatment Market” - Global forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global polycystic ovary syndrome (PCOS) treatment market during the forecast period (2023-2030)?

The global Polycystic Ovary Syndrome (PCOS) Treatment market is estimated to be valued at US$ 1,086.6 million in 2023 and is expected to exhibit a CAGR of 4.86% between 2023 and 2030.

What are the major factors driving the market growth?

Increasing prevalence of polycystic ovary syndrome is expected to drive the market.

Which is the leading drug type segment in the market?

Oral contraceptives are the leading drug type segment in the market.

What are the key factors hampering the market?

The factors which hampering the market are unavailability of U.S. Food and Drug Administration (FDA) approved drugs and alternative treatment options